177 related articles for article (PubMed ID: 18201240)
21. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of phosphorylated-STAT3 and phosphorylated-ERK protein in dermatofibrosarcoma protuberans.
Lin N; Urabe K; Moroi Y; Uchi H; Nakahara T; Dainichi T; Kokuba H; Tu Y; Furue M
Eur J Dermatol; 2006; 16(3):262-5. PubMed ID: 16709490
[TBL] [Abstract][Full Text] [Related]
23. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
Wick MR; Ritter JH; Lind AC; Swanson PE
Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
[TBL] [Abstract][Full Text] [Related]
24. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Abenoza P; Lillemoe T
Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
[TBL] [Abstract][Full Text] [Related]
25. The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans.
Maekawa T; Jinnin M; Ohtsuki M; Ihn H
Eur J Dermatol; 2011; 21(4):534-8. PubMed ID: 21697041
[TBL] [Abstract][Full Text] [Related]
26. A study of collagen refractility in dermatofibroma and dermatofibrosarcoma protuberans using diffractive microscopy.
Brailsford C; Khamdan F; Dirr MA; Sagut P; Nietert PJ; Elston D
J Cutan Pathol; 2024 Apr; 51(4):306-310. PubMed ID: 38124386
[TBL] [Abstract][Full Text] [Related]
27. Expression of cyclooxygenase-2 by equine ocular and adnexal squamous cell carcinomas.
Smith KM; Scase TJ; Miller JL; Donaldson D; Sansom J
Vet Ophthalmol; 2008 Sep; 11 Suppl 1():8-14. PubMed ID: 19046264
[TBL] [Abstract][Full Text] [Related]
28. Connexin 43 in Dermatofibroma and Dermatofibrosarcoma Protuberans: Diagnostic, Pathogenic, and Therapeutic Implications.
Fernandez-Flores A; Varela-Vazquez A; Mayan MD; Fonseca E
Am J Dermatopathol; 2023 Dec; 45(12):812-815. PubMed ID: 37982464
[TBL] [Abstract][Full Text] [Related]
29. Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma.
Wang L; Xiang YN; Zhang YH; Tu YT; Chen HX
Br J Dermatol; 2011 Jan; 164(1):135-40. PubMed ID: 20849518
[TBL] [Abstract][Full Text] [Related]
30. Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases.
Reimann JD; Fletcher CD
Am J Surg Pathol; 2007 Sep; 31(9):1371-7. PubMed ID: 17721193
[TBL] [Abstract][Full Text] [Related]
31. Dermatofibroma Versus Dermatofibrosarcoma Protuberans: A Nuclear Morphology Study.
Khamdan F; Brailsford C; Dirr MA; Sagut P; Nietert PJ; Elston D
Am J Dermatopathol; 2023 Sep; 45(9):631-634. PubMed ID: 37625803
[TBL] [Abstract][Full Text] [Related]
32. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
34. Giant cell fibroblastoma in a child misdiagnosed as a dermatofibroma.
Nguyen CM; Burch JM; Fitzpatrick JE; Peterson SL; Weston WL
Pediatr Dermatol; 2002; 19(1):28-32. PubMed ID: 11860566
[TBL] [Abstract][Full Text] [Related]
35. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans.
Cribier B; Noacco G; Peltre B; Grosshans E
J Am Acad Dermatol; 2002 Mar; 46(3):408-13. PubMed ID: 11862177
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and differential diagnosis of dermatofibrosarcoma protuberans: Utility of high-resolution dynamic contrast-enhanced (DCE) MRI.
Yu Q; Zhu Y; Huang R; Li Y; Song L; Zhang X; Tang M; Gu Q; Li P; Zhou N; Li Y
Skin Res Technol; 2022 Sep; 28(5):651-663. PubMed ID: 35639715
[TBL] [Abstract][Full Text] [Related]
37. [Dermatofibrosarcoma Darier and Ferrand. Immunohistochemistry study of 38 cases. Research on a specific marker].
Declerck D; Claye C; Rotteleur G; Lecomte-Houcke M
Ann Pathol; 1997 Oct; 17(5):324-8. PubMed ID: 9471146
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of cyclooxygenase 2 and Bcl-2 for cervical lymph node metastasis in mucoepidermoid carcinoma.
Zyada MM; Grawish ME; Elsabaa HM
Ann Diagn Pathol; 2009 Oct; 13(5):313-21. PubMed ID: 19751908
[TBL] [Abstract][Full Text] [Related]
39. Fat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans.
Schechter SA; Bresler SC; Patel RM
J Cutan Pathol; 2020 Oct; 47(10):913-916. PubMed ID: 32412128
[TBL] [Abstract][Full Text] [Related]
40. Possible contribution of PDGF-BB-induced autophagy in dermatofibrosarcoma protuberans: Autophagy marker Atg5 could be a differential marker between dermatofibrosarcoma protuberans and dermatofibroma.
Motegi SI; Fujiwara C; Sekiguchi A; Yamazaki S; Yokoyama Y; Yasuda M; Ishikawa O
J Dermatol Sci; 2019 Feb; 93(2):139-141. PubMed ID: 30704939
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
